Adalimumab

Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α) .

Product Specifications

CAS Number

[331731-18-1]

Product Name Alternative

Anti-Human TNF-alpha, Human Antibody

UNSPSC

12352203

Target

Bacterial; TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Anti-infection; Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/Adalimumab.html

Purity

99.90

Solubility

H2O

Smiles

[Adalimumab]

Molecular Weight

(145.43 kDa)

References & Citations

[1]Ternant D, et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015 Feb;79 (2) :286-97.|[2]Oberoi R, et al. Targeting Tumor Necrosis Factor-α with Adalimumab: Effects on Endothelial Activation and Monocyte Adhesion. PLoS One. 2016 Jul 28;11 (7) :e0160145.